Promising patient trials surrounding the medication Retatrutide , specifically the 120 milligram formulation referred to as ZPHC, reveal a impressive benefit on body mass loss and linked chronic conditions . Experts believe that this innovative compound, affecting both GLP-1 and GIP receptors ,